Viral Hepatitis

You have full text access to this OnlineOpen article

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial†

  1. Gregory T. Everson1,‡,*,
  2. John C. Hoefs2,
  3. Leonard B. Seeff3,
  4. Herbert L. Bonkovsky4,
  5. Deepa Naishadham5,
  6. Mitchell L. Shiffman6,
  7. Jeffrey A. Kahn7,
  8. Anna S. F. Lok8,
  9. Adrian M. Di Bisceglie9,
  10. William M. Lee10,
  11. Jules L. Dienstag11,
  12. Marc G. Ghany12,
  13. Chihiro Morishima13

Article first published online: 28 NOV 2006

DOI: 10.1002/hep.21440

Issue

Hepatology

Hepatology

Volume 44, Issue 6, pages 1675–1684, December 2006

Additional Information

How to Cite

Everson, G. T., Hoefs, J. C., Seeff, L. B., Bonkovsky, H. L., Naishadham, D., Shiffman, M. L., Kahn, J. A., Lok, A. S. F., Di Bisceglie, A. M., Lee, W. M., Dienstag, J. L., Ghany, M. G. and Morishima, C. (2006), Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology, 44: 1675–1684. doi: 10.1002/hep.21440

Author Information

  1. 1

    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO

  2. 2

    Division of Gastroenterology, University of California—Irvine, Irvine, CA

  3. 3

    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  4. 4

    Departments of Medicine and Molecular & Structural Biology and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, CT

  5. 5

    New England Research Institutes, Watertown, MA

  6. 6

    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA

  7. 7

    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA

  8. 8

    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI

  9. 9

    Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO

  10. 10

    Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX

  11. 11

    Gastrointestinal Unit (Medical Services), Massachusetts General Hospital and the Department of Medicine, Harvard Medical School, Boston, MA

  12. 12

    Liver Diseases Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  13. 13

    Department of Laboratory Medicine, University of Washington, Seattle, WA

  1. ‡

    fax: 303-372-8868

*Professor of Medicine, Director of Hepatology, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B-154, Denver, CO 80262

  1. †

    Potential conflict of interest: Dr. Everson is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Shiffman is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. He also advises for and received grants from Schering-Plough. He is a consultant and advises for Valeant. He also advises for Novartis. Dr. Hoefs is on the speakers' bureau of Roche. Dr. Bonkovsky is on the speaker's bureau of and received grants from Roche. He is on the speakers' bureau of Schering-Plough. Dr. Kahn is on the speakers' bureau of Gilead. He is a consultant and is on the speakers' bureau of Roche. Dr. Lok is a consultant for, advises, and received grants from Roche, GlaxoSmithKline, Gilead, Idenix, Innogenetics, and Bristol-Myers Squibb. She received grants from Schering-Plough and Valeant. She owns stock in, is a consultant, and advises for Andays. She is a consultant and advises for Pharmasset. Dr. Di Bisceglie is a consultant for and received grants from Roche. Dr. Lee received grants from Roche

  2. ‡

    fax: 303-372-8868

  3. This is publication number 19 from the HALT-C Trial Group.

Publication History

  1. Issue published online: 28 NOV 2006
  2. Article first published online: 28 NOV 2006
  3. Manuscript Accepted: 21 SEP 2006
  4. Manuscript Received: 26 APR 2006

Funded by

  • NIDDKD. Grant Numbers: N01-DK-9-2326, M01RR-06192, N01-DK-9-2324, N01-DK-9-2319, M01RR-01066, N01-DK-9-2327, M01RR-00051, N01-DK-9-2320, M01RR-00827, N01-DK-9-2321, M01RR-00633, N01-DK-9-2325, M01RR-00043, N01-DK-9-2323, M01RR-00042, N01-DK-9-2322, M01RR-00065, N01-DK-9-2318, N01-DK-9-2328

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (352K)

REFERENCES

  • 1
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–562.
  • 2
    Armstrong GL, Simard EP, Wasley A, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus (HCV) infection in the United States, 1999–2002 [Abstract]. Ann Intern Med 2006; 144: 705–714.
  • 3
    Alter MJ. Epidemiology of hepatitis C. HEPATOLOGY 1997; 26( Suppl 1): 62S–65S.
    Direct Link:
  • 4
    Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. HEPATOLOGY 2000; 31: 777–782.
    Direct Link:
  • 5
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortalty, and costs in the United States. Am J Public Health 2000; 90: 1562–1569.
  • 6
    Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36: S35–S46.
    Direct Link:
  • 7
    Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17–35.
  • 8
    Afdahl NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24: 3–8.
  • 9
    Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B hepatitis: a National Heart, Lung and Blood Institute collaborative study. HEPATOLOGY 2001; 33: 455–463.
    Direct Link:
  • 10
    El Serag. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27–S34.
  • 11
    National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002-June 10–12, 2002. HEPATOLOGY 2002;36: S3–S220.
  • 12
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–965.
  • 13
    Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
  • 14
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 15
    Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Controlled Clinical Trials 2004; 25: 472–492.
  • 16
    Searle J, Leggett BA, Crawford DHG, Powell LW. Iron storage diseases. In: SweenRNM, BurtAD, PortmannBC, IshakKG, ScheuerPJ, AnthonyPP, eds. Pathology of the Liver. 4th ed. Edinburgh: Churchill Livingstone, 2002: 257–272.
  • 17
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.
  • 18
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–2474.
    Direct Link:
  • 19
    Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose on virologic response in patients with chronic hepatitis C. Gastroenterology 2006.
  • 20
    Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology 2004; 126: 1015–1023.
  • 21
    Everson GT. Management of cirrhosis due to chronic hepatitis C. J HEPATOLOGY 2005; 42: S65–S74.
  • 22
    McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–1069.
  • 23
    Everson GT, Trotter JF, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. HEPATOLOGY 2005; 42: 255–262.
    Direct Link:
  • 24
    Forns X G-RM, Serrano T, Feliu A, Suarez F, de la Mat, Garcia-Valdecasas JC, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389–396.
  • 25
    Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350–355.
    Direct Link:
  • 26
    Strader DB, Wright T, Thomas DL, Seeff LB. AASLD Practice Guideline: Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 1147–1171.
    Direct Link:
  • 27
    Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. HEPATOLOGY 2005; 42: 282–292.
    Direct Link:
View Full Article (HTML) Get PDF (352K)